Tillotts Pharma AG
Tillotts Pharma AG is a fast-growing specialty pharmaceutical company committed to improving care for people with gastrointestinal diseases. It collaborates with healthcare professionals and GI-experts to develop and market medicines for digestive system diseases. The company has a global presence, with products available in over 65 countries, and is part of the Japanese Zeria Group. It focuses on innovative treatments, controlled release technologies, and supporting healthcare professionals through education and partnerships.
Industries
Nr. of Employees
large (251-1000)
Tillotts Pharma AG
Baslerstrasse 15, CH-4310 Rheinfelden, Switzerland
Patents
Products
Mesalazine-based oral formulations for ulcerative colitis
Oral mesalazine formulations indicated for induction and maintenance of remission in ulcerative colitis (marketed product range referenced on site).
Budesonide oral formulations for localized GI inflammation
Oral budesonide formulations intended to provide high local anti‑inflammatory effect in the gut for selected intestinal inflammatory conditions.
Oral therapy for Clostridioides difficile infection (CDI)
Oral tablets indicated for treatment of C. difficile infection with a focus on intestinal targeting and local activity.
Peppermint oil oral formulation for symptomatic IBS
Oral peppermint oil preparation indicated for symptomatic relief of painful bowel cramps and bloating in irritable bowel syndrome.
Mesalazine-based oral formulations for ulcerative colitis
Oral mesalazine formulations indicated for induction and maintenance of remission in ulcerative colitis (marketed product range referenced on site).
Budesonide oral formulations for localized GI inflammation
Oral budesonide formulations intended to provide high local anti‑inflammatory effect in the gut for selected intestinal inflammatory conditions.
Oral therapy for Clostridioides difficile infection (CDI)
Oral tablets indicated for treatment of C. difficile infection with a focus on intestinal targeting and local activity.
Peppermint oil oral formulation for symptomatic IBS
Oral peppermint oil preparation indicated for symptomatic relief of painful bowel cramps and bloating in irritable bowel syndrome.
Services
Evaluation and integration of in‑licensing and acquisition opportunities; commercial partnerships for regional distribution and co‑marketing.
Manufacturing operations and production services provided via onshore contract manufacturing site(s), including liquid‑fill capsule capability.
Adverse event reporting, case processing, medical information services and product safety contacts for marketed products.
Support for investigator‑initiated clinical research, collaboration with scientific advisory board and academic partners.
Design and delivery of educational events and workshops for clinicians focused on gastrointestinal disease management.
Evaluation and integration of in‑licensing and acquisition opportunities; commercial partnerships for regional distribution and co‑marketing.
Manufacturing operations and production services provided via onshore contract manufacturing site(s), including liquid‑fill capsule capability.
Adverse event reporting, case processing, medical information services and product safety contacts for marketed products.
Support for investigator‑initiated clinical research, collaboration with scientific advisory board and academic partners.
Design and delivery of educational events and workshops for clinicians focused on gastrointestinal disease management.
Expertise Areas
- Gastrointestinal therapeutics (inflammatory bowel disease, C. difficile, IBS)
- Controlled‑release oral drug delivery
- Clinical trial collaboration and investigator‑initiated trials
- Pharmacovigilance and drug safety
Key Technologies
- Colon‑targeting controlled‑release coatings for oral dosage forms
- Multiparticulate controlled‑release delivery systems
- Liquid fill hard‑shell capsule manufacturing
- Site‑specific oral release mechanisms (pH/microbiota‑responsive coatings)
News & Updates
RHEINFELDEN, Switzerland, February 14, 2025 – Tillotts Pharma AG celebrates its 15th anniversary as part of the Zeria Group.
RHEINFELDEN, Switzerland, November 27, 2024 - Tillotts Pharma AG partners with Pioneer for marketing and distribution in China.
Newark, DE, USA, 10 June 2024, Mage announces dosing of the first subject in a Phase 1 trial.
RHEINFELDEN, Switzerland, February 14, 2025 – Tillotts Pharma AG celebrates its 15th anniversary as part of the Zeria Group.
RHEINFELDEN, Switzerland, November 27, 2024 - Tillotts Pharma AG partners with Pioneer for marketing and distribution in China.
Newark, DE, USA, 10 June 2024, Mage announces dosing of the first subject in a Phase 1 trial.